Quellis Biosciences on Muck Rack

Quellis Biosciences

As seen in: The Journal of Allergy & Clinical Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Quellis

Contact Quellis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

QLS-215 is a Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor in Development for Treatment of HAE

|
By Pradeep Bista, Tomas Kiselak, Peter Harwin, Quellis Biosciences, Vahe Bedian
| The Journal of Allergy & Clinical Immunology Verified
Inhibition of plasma kallikrein (pKal) activity is a validated mechanism for prevention of HAE attacks. High potency and long duration of action are key drivers of prophylactic efficacy of pKal inhibitors but both attributes are not currently available in the same HAE treatment. We sought to generate a monoclonal antibody (mAb) pKal inhibitor with both high potency and long duration of action.
Open in Who Shared View Duplicates (155) Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified